secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kinnate Biopharma Inc. (—)
CIK:        0001797768
Form:       8-K
Filed at:   2023-09-18T23:59:59+00:00
Accession:  0001140361-23-044353
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01, 2.05, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Kinnate cuts workforce 70%, reprioritizes pipeline; cash runway into Q2 2026
----------------------------------------------------------------------------

- Workforce reduction of ~70% to 28 employees; China subsidiary Kinnjiu separation.
- One-time severance cost ~$2.0M in Q3 2023; plan completion expected in Q4 2023.
- Cash $204.3M as of June 30, 2023; expected runway into at least Q2 2026.
- Exarafenib combo in NRAS mutant melanoma: 38% ORR; two doses to be selected in Q4 2023.
- KIN-8741 IND filing and CDK4 candidate nomination planned for Q4 2023; KIN-7136 paused.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1797768/000114036123044353/0001140361-23-044353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1797768/000114036123044353/ef20010841_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-044353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer